Résumé
Dans le cancer du sein, de nombreux facteurs pronostiques et prédictifs sont accessibles, ces facteurs permettent d’évaluer l’évolution de la maladie mais aussi d’affiner le choix d’une prise en charge thérapeutique. Le statut d’envahissement ganglionnaire (positif ou atients) est un des plus importants paramètres pronostiques indépendants [1]. Les patientes montrant un envahissement ganglionnaire négatif présentent une maladie à bas ou moyen risque alors que les malades montrant au moins un ganglion envahi sont d’emblée considérées à moyen ou haut risque [2]. Le statut ganglionnaire doit être considéré comme un facteur pronostique » pur « et non comme un facteur prédictif permettant de prédire la réponse au traitement
Preview
Unable to display preview. Download preview PDF.
Références
Mamounas EP (2009) Age and l 1. ymph node status in breast cancer: not a straightforward relationship. J Clin Oncol 27: 2900–2901
Goldhirsch A, Glick JH, Gelber RD et al. (2005) Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16: 1569–1583
Lonning PE (2007) Breast cancer prognostication and prediction: are we making progress? Ann Oncol 18: viii3–viii7
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687–1717
Lonning PE, Knappskog S, Staalesen V et al. (2007) Breast cancer prognostication and prediction in the postgenomic era. Ann Oncol 18: 1293–1306
Singletary SE, Allred C, Ashley P et al. (2002) Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 20: 3628–3636
Bloom HJ, Richardson WW (1957) Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11: 359–377
Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with longterm follow-up. Histopathology 19: 403–410
Milano G, Moll JL, Formento JL et al. (1983) Simultaneous micro measurement of steroid receptors in breast cancer. Br J Cancer 48: 579–584
Romain S, Formento JL, Guirou O et al. (1994) Determination of oestrogen receptors by enzyme immunoassay. Technical differences between laboratories and their consequences. Eur J Cancer 30A: 740–746
Blankenstein MA (1990) Comparison of ligand binding assay and enzyme immunoassay of oestrogen receptor in human breast cancer cytosols. Experience of the E.O.R.T.C. Receptor Group. Breast Cancer Res Treat 17: 91–98
Blancas I, Gomez FJ, Bermejo B et al. (2009) Outcome differences between patients with node-negative breast cancer classified according to the st. Gallen risk categories. Clin Breast Cancer 9: 231–236
Look MP, van Putten WL, Duffy MJ et al. (2002) Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 94: 116–128
Truong PT, Yong CM, Abnousi F et al. (2005) Lymphovascular invasion is associated with reduced locoregional control and survival in women with node-negative breast cancer treated with mastectomy and systemic therapy. J Am Coll Surg 200: 912–921
Truong PT, Lesperance M, Li KH et al. (2010) Micrometastatic node-positive breast cancer: long-term outcomes and identification of high-risk subsets in a large population-based series. Ann Surg Oncol 17: 2138–2146
Rights and permissions
Copyright information
© 2012 Springer-Verlag France, Paris
About this paper
Cite this paper
Chamorey, E. et al. (2012). Épidémiologie et diversité des cancers du sein N− Étude sur une cohorte de plus de 5 000 patientes traitées au Centre Antoine Lacassagne (Nice, France). In: Cancer du sein. Springer, Paris. https://doi.org/10.1007/978-2-8178-0245-9_28
Download citation
DOI: https://doi.org/10.1007/978-2-8178-0245-9_28
Publisher Name: Springer, Paris
Print ISBN: 978-2-8178-0244-2
Online ISBN: 978-2-8178-0245-9